As young people age out of their pediatric or adolescent HIV care and treatment programs, they require different types of support. However, there is a lack of understanding and planning for potential transitions in care for young people in most countries. As a result, HP+ created the Pediatric HIV Transition Model to inform target setting, forecasting, and planning for young people’s transitions in care in PEPFAR-supported countries. This model projects the number of children, adolescents, and young adults ages 0-24 on antiretroviral therapy (ART) who are eligible for transitions in care and switching to tenofovir/lamivudine/dolutegravir (TLD) or another newly-introduced regimen. Users can develop up to three scenarios for ART coverage projections and results are disaggregated by subnational unit, gender, and single-year age band.
Information presented on this website is considered public information and may be distributed or copied freely unless identified as being subject to copyright protection.